Blis Technologies

We currently market three strains of probiotic bacteria: BLIS K12™, BLIS M18™ and BLIS Q24®. BLIS K12™ and BLIS M18™ are both strains of Streptococcus salivarius, and occur naturally in the oral cavity. However, only around 2% of the population have these healthy bacteria at levels high enough to be effective. BLIS K12™ was our first discovery. We know that BLIS K12™ has a positive impact on the ear nose and throat health of infants and children, and is also effective in improving bad breath (halitosis). The second strain BLIS M18™ promotes a healthy bacterial balance for dental health. Our third strain, BLIS Q24® a major breakthrough in the care of the skin microbiome because it contains 150 million CFU of live bacteria with every application that work with your skin to bring it to its healthiest balance. Our oral strains were discovered by Professor John Tagg while at the University of Otago Microbiology Department. He extensively catalogued a collection of more than 2000 of these bacteria strains over a period of more than 30 years. Those bacteria were then acquired by BLIS Technologies with the first product – ThroatGuard – launched in 2002. Today, the BLIS portfolio consists of a range of products to support throat immunity, oral care, halitosis and travel immunity, and the research continues with many exciting projects on the horizon. Read more about BLIS Q24® and Unconditional Skincare Co. at https://unconditionalskincare.com All our products are developed and manufactured at our headquarters in Dunedin, New Zealand.